Results 11 to 20 of about 2,147 (178)

Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis

New England Journal of Medicine, 2021
Interleukin-1 has been implicated as a mediator of recurrent pericarditis. The efficacy and safety of rilonacept, an interleukin-1α and interleukin-1β cytokine trap, were studied previously in a phase 2 trial involving patients with recurrent pericarditis.We conducted a phase 3 multicenter, double-blind, event-driven, randomized-withdrawal trial of ...
Fang Fang, Sushil Luis
exaly   +6 more sources

Rilonacept and Anakinra in Recurrent Pericarditis: A Systematic Review and Meta-Analysis [PDF]

Cureus, 2022
Interleukin 1 (IL-1) has been indicated as a mediator of recurrent pericarditis. Rilonacept, a soluble IL-1 receptor chimeric fusion protein neutralizing interleukin 1 alpha (IL-1α) and interleukin 1 beta (IL-1β), has demonstrated promising results in a phase II study in recurrent or refractory pericarditis.
Affas, Ziad R, Rasool, Banan Q, Sebastian, Sneha A, Affas, Rafe S, Mohamadtahr, Sayran K, Saoor, Nagham H, Mohammad, Aya N, Saoor, Ghada H, Husain, Bzhar A, Touza, Rowaid, Touza, Ghaid, Amen, Shwan, Nazzaro, William   +12 more
core   +7 more sources

Mechanistic Insights and Emerging Therapeutic Strategies in Recurrent Pericarditis [PDF]

Methodist DeBakey Cardiovascular Journal
Recurrent pericarditis is a heterogeneous and often debilitating inflammatory disorder characterized by recurrent flares following a symptom-free interval of at least 4 to 6 weeks.
Mohammad A. Alqahtani, Tom Kai Ming Wang, Allan L. Klein   +2 more
doaj   +2 more sources

Rilonacept and canakinumab [PDF]

British Journal of Clinical Pharmacology, 2011
Two new orphan medicines, rilonacept [1, 2] (Regeneron®) and canakinumab [3, 4] (Ilaris®), are indicated for the treatment of cryopyrin-associated periodic syndromes (CAPS). CAPS occur in a group of rare, inherited, inflammatory diseases where patients have a mutation in the NLRP3 (nucleotide-binding domain, leucine-rich family, pyrin domain-containing-
Eline A, Dubois, Robert, Rissmann, Adam F, Cohen   +2 more
openaire   +3 more sources

Constrictive-effusive pericarditis as presenting feature of IgG4-related disease (IgG4-RD): a case report [PDF]

Journal of Medical Case Reports
Background IgG4-Related Disease (IgG4-RD) is a fibroinflammatory disorder initially identified as autoimmune pancreatitis but subsequently shown in numerous other organs with common pathological hallmarks.
Robert Fekete
doaj   +2 more sources

Longitudinal cardiac magnetic resonance imaging following clinical response to rilonacept and prior to recurrence upon treatment suspension: a RHAPSODY subgroup analysis [PDF]

European Heart Journal Cardiovascular Imaging
AIMS: In the Phase 3 trial, RHAPSODY, rilonacept effectively resolved active pericarditis recurrences, and long-term treatment led to sustained pericarditis recurrence risk reduction.
John Paolini, Sushil Luis, Antonio Brucato   +2 more
exaly   +3 more sources

Clinical Utility of Rilonacept for the Treatment of Recurrent Pericarditis: Design, Development, and Place in Therapy [PDF]

Drug Design, Development and Therapy
Panayotis K Vlachakis, Panagiotis Theofilis, Stergios Soulaidopoulos, Emilia Lazarou, Konstantinos Tsioufis, George Lazaros First Cardiology Department, School of Medicine, Hippokration General Hospital, National and Kapodistrian University of Athens ...
Vlachakis PK, Theofilis P, Soulaidopoulos S, Lazarou E, Tsioufis K, Lazaros G   +5 more
doaj   +3 more sources

Pericarditis at the crossroads: Unlocking the next wave of therapies [PDF]

International Journal of Cardiology: Heart & Vasculature
Pericarditis is an inflammation of the pericardial sac with different aetiologies. While often self-limited, up to 30 % of cases recur or become chronic, causing significant morbidity. Traditional treatments – nonsteroidal anti-inflammatory drugs (NSAIDs)
Massimo Imazio, Francesco Venturelli, Maria Cristina Tomat, Giulio Savonitto, Davide Stolfo, Valentino Collini   +5 more
doaj   +2 more sources

Multiyear Recurrent Pericarditis Disease Duration: Clinical Outcomes After Cessation of Long‐Term Interleukin‐1 Pathway Inhibition Provide Insights for Chronic Management

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Recurrent pericarditis is an interleukin‐1–mediated chronic autoinflammatory disease. The phase 3 study RHAPSODY (Rilonacept Inhibition of IL‐1 Alpha and IL‐1 Beta for Recurrent Pericarditis: a Pivotal Symptomatology and Outcomes Study ...
Lucia Trotta, Massimo Imazio, Emanuele Bizzi, Massimo Pancrazi, Alessandro Andreis, Antonella Insalaco, Sheldon Wang, JoAnn Clair, Allan L. Klein, Enrico Tombetti, Antonio Brucato, John F. Paolini   +11 more
doaj   +2 more sources

Long term management of patients with cryopyrin-associated periodic syndromes (CAPS): focus on rilonacept (IL-1 Trap) [PDF]

Biologics: Targets & Therapy, 2008
Leigh D Church1, Sinisa Savic2, Michael F McDermott21Department of Rheumatology, Division of Immunity, Infection and Inflammation, Institute for Biomedical Research, The University of Birmingham, Birmingham, UK; 2Section of Musculoskeletal Disease, Leeds
Leigh D Church, Sinisa Savic, Michael F McDermott   +2 more
doaj   +2 more sources